AU2023219770A1 - Granulocyte-macrophage colony-stimulating factor-based treatments for neurodegenerative or neurological diseases or disorders - Google Patents

Granulocyte-macrophage colony-stimulating factor-based treatments for neurodegenerative or neurological diseases or disorders Download PDF

Info

Publication number
AU2023219770A1
AU2023219770A1 AU2023219770A AU2023219770A AU2023219770A1 AU 2023219770 A1 AU2023219770 A1 AU 2023219770A1 AU 2023219770 A AU2023219770 A AU 2023219770A AU 2023219770 A AU2023219770 A AU 2023219770A AU 2023219770 A1 AU2023219770 A1 AU 2023219770A1
Authority
AU
Australia
Prior art keywords
csf
patient
activity
expression
neurodegenerative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2023219770A
Other languages
English (en)
Inventor
Timothy Boyd
Ila JOSHI
Edwin ROCK
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Partner Therapeutics Inc
Original Assignee
Partner Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Partner Therapeutics Inc filed Critical Partner Therapeutics Inc
Publication of AU2023219770A1 publication Critical patent/AU2023219770A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU2023219770A 2022-02-11 2023-02-10 Granulocyte-macrophage colony-stimulating factor-based treatments for neurodegenerative or neurological diseases or disorders Pending AU2023219770A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263309220P 2022-02-11 2022-02-11
US63/309,220 2022-02-11
PCT/US2023/062374 WO2023154855A2 (en) 2022-02-11 2023-02-10 Granulocyte-macrophage colony-stimulating factor-based treatments for neurodegenerative or neurological diseases or disorders

Publications (1)

Publication Number Publication Date
AU2023219770A1 true AU2023219770A1 (en) 2024-08-22

Family

ID=87565120

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2023219770A Pending AU2023219770A1 (en) 2022-02-11 2023-02-10 Granulocyte-macrophage colony-stimulating factor-based treatments for neurodegenerative or neurological diseases or disorders

Country Status (8)

Country Link
US (1) US20250134959A1 (enExample)
EP (1) EP4475874A4 (enExample)
JP (1) JP2025508308A (enExample)
KR (1) KR20240147980A (enExample)
CN (1) CN118660715A (enExample)
AU (1) AU2023219770A1 (enExample)
CA (1) CA3242855A1 (enExample)
WO (1) WO2023154855A2 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023235795A2 (en) * 2022-06-01 2023-12-07 Partner Therapeutics, Inc. Granulocyte-macrophage colony-stimulating factor-based treatments for pulmonary or respiratory diseases or disorders
WO2025168003A1 (zh) * 2024-02-06 2025-08-14 上海市第四人民医院 一种治疗神经退行性疾病的药物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7785601B2 (en) * 2002-12-31 2010-08-31 Sygnis Bioscience Gmbh & Co. Kg Methods of treating neurological conditions with hematopoietic growth factors
WO2017185085A1 (en) * 2016-04-22 2017-10-26 Board Of Regents Of The University Of Nebraska Biomarkers for monitoring immune transformation
EP4103618A4 (en) * 2020-02-12 2024-05-01 The Scripps Research Institute LONG-ACTING GM-CSF AND METHODS OF USE

Also Published As

Publication number Publication date
CA3242855A1 (en) 2023-08-17
WO2023154855A2 (en) 2023-08-17
CN118660715A (zh) 2024-09-17
US20250134959A1 (en) 2025-05-01
EP4475874A4 (en) 2026-05-13
JP2025508308A (ja) 2025-03-26
KR20240147980A (ko) 2024-10-10
EP4475874A2 (en) 2024-12-18
WO2023154855A3 (en) 2023-10-05

Similar Documents

Publication Publication Date Title
EP3583125B1 (en) Albumin binding domain fusion proteins
Harari et al. Enhanced in vivo efficacy of a type I interferon superagonist with extended plasma half-life in a mouse model of multiple sclerosis
KR100439289B1 (ko) 인터로이킨-18수용체단백질
US10695404B2 (en) Treatment of steroid-induced hyperglycemia with fibroblast growth factor (FGF) 1 analogs
US20250134959A1 (en) Granulocyte-macrophage colony-stimulating factor-based treatments for neurodegenerative or neurological diseases or disorders
AU623698B2 (en) Macrophage-derived inflammatory mediator (mip-2)
JP2020517740A (ja) 神経変性疾患を治療するためのcd14アンタゴニスト抗体
JP7678802B2 (ja) Siglec-9ECD融合分子及びその使用方法
ITRM940794A1 (it) Antagonisti di interleuchina-6(il-6) che consistono di forme solubili del ricettore alfa di il-6, mutate nell'interfaccia che si lega a gp 130
CA2743394C (en) Il-4-derived peptides for modulation of the chronic inflammatory response and treatment of autoimmune diseases
WO2021063350A1 (zh) 一种融合蛋白及其应用
CN120897934A (zh) 抗pd-1/il-2融合蛋白、药物组合物和治疗应用
CN121002060A (zh) 犬il-13的犬抗体
US20070149439A1 (en) Pituitary adenylate cyclase-activating polypeptide (PACAP) is an anti-mitogenic signal for selected neuronal precursors in vivo
EP3917958A1 (en) Treatment of neurotoxicity and / or cytokine release syndrome
CN119013033A (zh) 白细胞介素-2突变蛋白、融合蛋白、药物组合物以及治疗应用
US20240361339A1 (en) Biomarkers for parkinson's disease
CN118043672A (zh) 帕金森病的生物标志物
WO2023235795A2 (en) Granulocyte-macrophage colony-stimulating factor-based treatments for pulmonary or respiratory diseases or disorders
US20240182535A1 (en) Granulocyte macrophage-colony stimulating factor mutants
HK40126456A (en) Albumin binding domain fusion proteins
HK40015886B (en) Albumin binding domain fusion proteins
HK40015886A (en) Albumin binding domain fusion proteins
JP2024542999A (ja) インターロイキン-34を標的とする化合物及び方法